Eagle Asset Management’s Ionis Pharmaceuticals IONS Stock Holding History

Eagle Asset Management’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-349,534	Closed	-$20.1M	–	658
2015 Q2	$20.1M	Sell	349,534 -730,694	-68%	-$46.5M	0.11%	220
2015 Q1	$68.8M	Sell	1,080,228 -229,724	-18%	-$15.6M	0.39%	83
2014 Q4	$80.9M	Sell	1,309,952 -23,225	-2%	-$1.15M	0.47%	63
2014 Q3	$51.8M	Buy	+1,333,177	New	+$47.2M	0.3%	117
2014 Q2	–	Sell	-688,006	Closed	-$29.7M	–	651
2014 Q1	$29.7M	Sell	688,006 -632,548	-48%	-$30.7M	0.16%	191
2013 Q4	$52.6M	Buy	1,320,554 +403,486	+44%	+$14.4M	0.3%	117
2013 Q3	$35.2M	Buy	+917,068	New	+$27.4M	0.17%	165

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Eagle Asset Management's IONS Position: Q3 2015 in Review

Eagle Asset Management sold out of Ionis Pharmaceuticals (IONS) in Q3 2015, closing a stake of 349,534 shares — an estimated $20.1M sold.

Eagle Asset Management first reported a position in IONS in Q3 2013 and held it in 7 quarters. The position peaked at $80.9M in Q4 2014. 314 funds tracked by Wall St. Rank hold IONS as of Q3 2015.

Eagle Asset Management reported no remaining Ionis Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
Eagle Asset Management sold 349,534 Ionis Pharmaceuticals shares in Q3 2015, an estimated $20.1M.
Eagle Asset Management first reported a position in Ionis Pharmaceuticals in Q3 2013 and held it in 7 quarters.
Eagle Asset Management's Ionis Pharmaceuticals position peaked at $80.9M in Q4 2014.
314 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2015.

Based on Eagle Asset Management's 13F filing for Q3 2015, filed 20 Oct 2015.